FGFR3 INHIBITOR COMPOUNDS

FGFR3 INHIBITOR COMPOUNDS

The present invention provides compounds of the formula:for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or canc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: METCALF, Andrew Terrance, WALLS, Shane Michael, CONDROSKI, Kevin Ronald, DILGER, Andrew Karl, ABRAHAM, Adedoyin David, KERCHER, Timothy Scott, URKALAN, Kaveri Balan, HAZLITT, Robert Alan, BUME, Desta Doro
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator METCALF, Andrew Terrance
WALLS, Shane Michael
CONDROSKI, Kevin Ronald
DILGER, Andrew Karl
ABRAHAM, Adedoyin David
KERCHER, Timothy Scott
URKALAN, Kaveri Balan
HAZLITT, Robert Alan
BUME, Desta Doro
description The present invention provides compounds of the formula:for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2023095122A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2023095122A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2023095122A13</originalsourceid><addsrcrecordid>eNrjZJB0c3cLMlbw9PPwdPIM8Q9ScPb3DfAP9XMJ5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8aHBRgZGxgaWpoZGRo6GxsSpAgCQGyDg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>FGFR3 INHIBITOR COMPOUNDS</title><source>esp@cenet</source><creator>METCALF, Andrew Terrance ; WALLS, Shane Michael ; CONDROSKI, Kevin Ronald ; DILGER, Andrew Karl ; ABRAHAM, Adedoyin David ; KERCHER, Timothy Scott ; URKALAN, Kaveri Balan ; HAZLITT, Robert Alan ; BUME, Desta Doro</creator><creatorcontrib>METCALF, Andrew Terrance ; WALLS, Shane Michael ; CONDROSKI, Kevin Ronald ; DILGER, Andrew Karl ; ABRAHAM, Adedoyin David ; KERCHER, Timothy Scott ; URKALAN, Kaveri Balan ; HAZLITT, Robert Alan ; BUME, Desta Doro</creatorcontrib><description>The present invention provides compounds of the formula:for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20230330&amp;DB=EPODOC&amp;CC=US&amp;NR=2023095122A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20230330&amp;DB=EPODOC&amp;CC=US&amp;NR=2023095122A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>METCALF, Andrew Terrance</creatorcontrib><creatorcontrib>WALLS, Shane Michael</creatorcontrib><creatorcontrib>CONDROSKI, Kevin Ronald</creatorcontrib><creatorcontrib>DILGER, Andrew Karl</creatorcontrib><creatorcontrib>ABRAHAM, Adedoyin David</creatorcontrib><creatorcontrib>KERCHER, Timothy Scott</creatorcontrib><creatorcontrib>URKALAN, Kaveri Balan</creatorcontrib><creatorcontrib>HAZLITT, Robert Alan</creatorcontrib><creatorcontrib>BUME, Desta Doro</creatorcontrib><title>FGFR3 INHIBITOR COMPOUNDS</title><description>The present invention provides compounds of the formula:for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJB0c3cLMlbw9PPwdPIM8Q9ScPb3DfAP9XMJ5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8aHBRgZGxgaWpoZGRo6GxsSpAgCQGyDg</recordid><startdate>20230330</startdate><enddate>20230330</enddate><creator>METCALF, Andrew Terrance</creator><creator>WALLS, Shane Michael</creator><creator>CONDROSKI, Kevin Ronald</creator><creator>DILGER, Andrew Karl</creator><creator>ABRAHAM, Adedoyin David</creator><creator>KERCHER, Timothy Scott</creator><creator>URKALAN, Kaveri Balan</creator><creator>HAZLITT, Robert Alan</creator><creator>BUME, Desta Doro</creator><scope>EVB</scope></search><sort><creationdate>20230330</creationdate><title>FGFR3 INHIBITOR COMPOUNDS</title><author>METCALF, Andrew Terrance ; WALLS, Shane Michael ; CONDROSKI, Kevin Ronald ; DILGER, Andrew Karl ; ABRAHAM, Adedoyin David ; KERCHER, Timothy Scott ; URKALAN, Kaveri Balan ; HAZLITT, Robert Alan ; BUME, Desta Doro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2023095122A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>METCALF, Andrew Terrance</creatorcontrib><creatorcontrib>WALLS, Shane Michael</creatorcontrib><creatorcontrib>CONDROSKI, Kevin Ronald</creatorcontrib><creatorcontrib>DILGER, Andrew Karl</creatorcontrib><creatorcontrib>ABRAHAM, Adedoyin David</creatorcontrib><creatorcontrib>KERCHER, Timothy Scott</creatorcontrib><creatorcontrib>URKALAN, Kaveri Balan</creatorcontrib><creatorcontrib>HAZLITT, Robert Alan</creatorcontrib><creatorcontrib>BUME, Desta Doro</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>METCALF, Andrew Terrance</au><au>WALLS, Shane Michael</au><au>CONDROSKI, Kevin Ronald</au><au>DILGER, Andrew Karl</au><au>ABRAHAM, Adedoyin David</au><au>KERCHER, Timothy Scott</au><au>URKALAN, Kaveri Balan</au><au>HAZLITT, Robert Alan</au><au>BUME, Desta Doro</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>FGFR3 INHIBITOR COMPOUNDS</title><date>2023-03-30</date><risdate>2023</risdate><abstract>The present invention provides compounds of the formula:for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2023095122A1
source esp@cenet
subjects CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
title FGFR3 INHIBITOR COMPOUNDS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A32%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=METCALF,%20Andrew%20Terrance&rft.date=2023-03-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2023095122A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true